« Back
Home /
BRCA1 Peptide - middle region (AAP33338)

BRCA1 Peptide - middle region (AAP33338)

Item no.	AAP33338
Manufacturer	AVIVA Systems Biology
Amount	100 ug
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Cholesterol & Lipid Metabolism Neural Transcription Factors Molecular Targets for Neuroscience Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Neural Epigenetics Protein Aggregation, Clearance & Misfolding By Cell Type Blastoma Carcinoma Hematology Lymphoma Myeloma Melanoma Sarcoma Peptides & Proteins Immunohistochemistry Western Blot Peptides By Organ Breast Cancer Neurodegeneration Markers
Type	Peptides
Format	Lyophilized powder
Applications	WB, IHC
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	BRCAI, BRCC1, IRIS, PSCP, RNF53
Similar products	BRCA1
Available
Description	This is a synthetic peptide designed for use in combination with anti-BRCA1 antibody (Catalog #: ARP33338_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Gene symbol	BRCA1
Protein size	1863
Molecular weight	208kDa
Product format	Lyophilized powder
Gene id	672
Reconstitution and storage	Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles.
Partner proteins	ETS2, CREBBP, EP300, MAP3K3, MED1, BRCA1, SMAD2, SMAD3, SMAD4, UBB, ACACA, ATR, BRCA2, CCNA1, CCNB1, CCND1, CDK2, CDK4, CSNK2B, E2F1, E2F4, FANCA, HDAC1, HDAC2, JUN, JUNB, JUND, LMO4, MSH2, MSH6, MYC, NFYA, NMI, NUFIP1, POU2F1, RAD51, RAD51, RB1, RBBP4, RBBP7, RBBP8, SP1, TP53, TP53, ABL1, ACACA, AKT1, AR, ATF1, ATR, AURKA, BAP1, BARD1, BRAP, BRCA1, BRCA2, BRCC3, BRIP1, CASP3, CCNA1, CCNA2, CCNB1, CCND1, CDK1, CDK2, CDK4, CDK7, CHEK2, CLSPN, COBRA1, CREBBP, CSNK2A1, CSNK2B, CSTF1, CTBP1, DCLRE1C, DHX9, E2F1, E2F4, ELK1, EP300, ESR1, FAM175A, FANCA, FANCD2, FHL2, GFI1B, H2AFX, HDAC1, HDAC2, IFI16, JAK1, JAK2, JUN, JUNB, JUND, KPNA2, KPNA6, LMO4, MAP3K3, MDC1, MED1, MED21, MLH1, MNAT1, MYC, NBN, NFKB1, NFYA, NMI, NUFIP1, POLR2A, POLR2K, POU2F1, PPP1CA, PSAP, RAD51, RB1, RBBP4, RBBP7, RBBP8, RELA, RFC1, SMAD2, SMAD3, SMAD4, SMARCA2, SMARCA4, SMC1A, SP1, STAT1, STAT3, STAT5A, TOP2A, TP53, TP53BP1, TRRAP, TUBA4A, TUBB, TUBG1, UBB, UBE2D3, UBE2L3, USF2, VCP, XRCC1, YY1, ZNF350, ABL1, ACACA, AKT1, APLP2, AR, ASM4, ATF1, ATM, ATR, AURKA, BACH1, BARD1, BLM, BRAP, BRCA1, BRCA2, BRCC3, BRD7, BRE, BRIP1, CCNA1, CCNA2, CCNB1, CCND1, CCNE1, CCR4, CDK1, CDK16, CDK2, CDK4, CDK5, CDK8, CDS1, CHEK2, CLSPN, COBRA1, CREB1, CREBBP, CSNK2A1, CSNK2B, CSTF1, CSTF2, CTBP1, CTCFL, DEF1, DHH1, DHX9, DNAJA3, E2F4, ELK4, EP300, ESR1, ETS1, FANCA, FANCD2, FHL2, FLI1, GTF2E1, GTF2F1, GTF2H4, H2AFX, H2AFY, HDAC1, HDAC2, HIST2H2AC, HIST2H3C, HSPA8, Ifi204, JAK1, JAK2, JUN, JUNB, JUND, KIF1B, KPNA2, LMO4, MAP3K3, MAP4K4, MDC1, MED1, MED13, MED17, MED21, MED23, MED24, MLH1, MLP2, MRE11A, MRPL39, MSH2, MSH3, MSH6, MYC, NBN, NCOA2, NCOA3, NFYA, NMI, NPM1, NUFIP1, NUP120, NUP133, NUP153, NUP170, NUP188, NUP2, ORC2L, ORC3L, PEG3, POLR2A, POM34, POU2F1, PPP1CA, PPP1CB, PPP1R3A, PRKDC, RAD50, RAD51, RB1, RBBP4, RBBP7, RBBP8, RBL1, RBL2, RELA, RFC1, RPL31, SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD2, SP1, SPT4, SPT5, STAT1, STAT5A, SUB1, TOP2A, TP53, TP53BP1, TUBG1, UBA1, UBC, UBE2D1, UBE2L3, UBE3A, UIMC1, USF2, VCP, WDR48, WNT2B, XIST, ZCCHC8, ZNF350
Description of target	The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. BRCA1 acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. BRCA1 plays a central role in DNA repair by facilitating cellular response to DNA repair. BRCA1 is required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. BRCA1 is involved in transcriptional regulation of P21 in response to DNA damage. BRCA1 is also required for FANCD2 targeting to sites of DNA damage.It may function as a transcriptional regulator. BRCA1 inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation.This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as BASC for BRCA1-associated genome surveillance complex. This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complex. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants have been described for this gene but only some have had their full-length natures identified.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

AAP33338-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug

available

Delivery expected until 10/30/2025

Express Delivery: Save 20 days

Compare

Add to wishlist

Get an offer